<DOC>
	<DOC>NCT00751621</DOC>
	<brief_summary>This study is a continuation of the study ZLB06_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.</brief_summary>
	<brief_title>Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<criteria>Subjects with primary humoral immunodeficiency, namely with a diagnosis of Common variable immunodeficiency (CVID) as defined by the PanAmerican Group for Immunodeficiency (PAGID) and the European Society for Immunodeficiencies (ESID), or Xlinked agammaglobulinemia (XLA) as defined by PAGID and ESID, or autosomal recessive agammaglobulinemia who have participated in the study ZLB06_001CR and who have tolerated IgPro well Written informed consent Hypoalbuminemia, proteinlosing enteropathies, and any proteinuria (defined as total urine protein concentration &gt; 0.2g/L) Other significant medical conditions that could increase the risk to the subject Females who are pregnant, breast feeding or planning a pregnancy during the course of the study Participation in a study with an investigational medicinal product within three months prior to enrollment, except for ZLB06_001CR Evidence of uncooperative attitude Any condition that is likely to interfere with evaluation of the IMP or satisfactory conduct of the study Subjects who are employees at the investigational site, relatives or spouse of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Immune globulin subcutaneous</keyword>
	<keyword>SCIG</keyword>
	<keyword>primary immunodeficiency</keyword>
	<keyword>PID</keyword>
</DOC>